{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T04:45:41Z","timestamp":1789101941587,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-025-11300-w","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T05:44:07Z","timestamp":1764654247000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of atranorin on the proliferation, apoptosis and metastasis of two different gastric cancer cell lines and exploring underlying mechanisms"],"prefix":"10.1007","volume":"53","author":[{"given":"Nihal","family":"Almuraikhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleh Hussain A.","family":"Almasabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulfattah Y.","family":"Alhazmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman","family":"Almohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jameel","family":"Barnawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salah","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Alhazmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"11300_CR1","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/s0140-6736(25)00052-2","volume":"405","author":"R Sundar","year":"2025","unstructured":"Sundar R, Nakayama I, Markar SR, Shitara K, van Laarhoven HWM, Janjigian YY et al (2025) Gastric cancer. Lancet 405:2087\u20132102. https:\/\/doi.org\/10.1016\/s0140-6736(25)00052-2","journal-title":"Lancet"},{"key":"11300_CR2","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1053\/j.gastro.2023.12.022","volume":"166","author":"YC Chen","year":"2024","unstructured":"Chen YC, Malfertheiner P, Yu HT, Kuo CL, Chang YY, Meng FT et al (2024) Global prevalence of Helicobacter pylori infection and incidence of gastric cancer between 1980 and 2022. Gastroenterology 166:605\u2013619. https:\/\/doi.org\/10.1053\/j.gastro.2023.12.022","journal-title":"Gastroenterology"},{"key":"11300_CR3","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s10555-020-09925-3","volume":"39","author":"RE Sexton","year":"2020","unstructured":"Sexton RE, Al Hallak MN, Diab M, Azmi AS (2020) Gastric cancer: a comprehensive review of current and future treatment strategies. Cancer Metastasis Rev 39:1179\u20131203. https:\/\/doi.org\/10.1007\/s10555-020-09925-3","journal-title":"Cancer Metastasis Rev"},{"key":"11300_CR4","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/s0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F (2020) Gastric cancer. Lancet 396:635\u2013648. https:\/\/doi.org\/10.1016\/s0140-6736(20)31288-5","journal-title":"Lancet"},{"key":"11300_CR5","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.trecan.2024.03.008","volume":"10","author":"T Yasuda","year":"2024","unstructured":"Yasuda T, Wang YA (2024) Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development. Trends Cancer 10:627\u2013642. https:\/\/doi.org\/10.1016\/j.trecan.2024.03.008","journal-title":"Trends Cancer"},{"key":"11300_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102317","volume":"52","author":"S Ouyang","year":"2022","unstructured":"Ouyang S, Li H, Lou L, Huang Q, Zhang Z, Mo J et al (2022) Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer. Redox Biol 52:102317. https:\/\/doi.org\/10.1016\/j.redox.2022.102317","journal-title":"Redox Biol"},{"key":"11300_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112375","volume":"145","author":"JA Malik","year":"2022","unstructured":"Malik JA, Ahmed S, Jan B, Bender O, Al Hagbani T, Alqarni A et al (2022) Drugs repurposed: an advanced step towards the treatment of breast cancer and associated challenges. Biomed Pharmacother 145:112375. https:\/\/doi.org\/10.1016\/j.biopha.2021.112375","journal-title":"Biomed Pharmacother"},{"key":"11300_CR8","doi-asserted-by":"publisher","first-page":"9722","DOI":"10.3390\/ijms22189722","volume":"22","author":"S Maniam","year":"2021","unstructured":"Maniam S, Maniam S (2021) Small molecules targeting programmed cell death in breast cancer cells. Int J Mol Sci 22:9722. https:\/\/doi.org\/10.3390\/ijms22189722","journal-title":"Int J Mol Sci"},{"key":"11300_CR9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41392-020-0134-x","volume":"5","author":"J Fares","year":"2020","unstructured":"Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y (2020) Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther 5:28\u201335. https:\/\/doi.org\/10.1038\/s41392-020-0134-x","journal-title":"Signal Transduct Target Ther"},{"key":"11300_CR10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/14737140.2020.1718496","volume":"20","author":"K Stoletov","year":"2020","unstructured":"Stoletov K, Beatty PH, Lewis JD (2020) Novel therapeutic targets for cancer metastasis. Expert Rev Anticancer Ther 20:97\u2013109. https:\/\/doi.org\/10.1080\/14737140.2020.1718496","journal-title":"Expert Rev Anticancer Ther"},{"key":"11300_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.semcancer.2022.10.006","volume":"87","author":"M Castaneda","year":"2022","unstructured":"Castaneda M, den Hollander P, Kuburich NA, Rosen JM, Mani SA (2022) Mechanisms of cancer metastasis. Semin Cancer Biol 87:17\u201331. https:\/\/doi.org\/10.1016\/j.semcancer.2022.10.006","journal-title":"Semin Cancer Biol"},{"key":"11300_CR12","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","volume":"77","author":"R Lugano","year":"2020","unstructured":"Lugano R, Ramachandran M, Dimberg A (2020) Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci 77:1745\u20131770. https:\/\/doi.org\/10.1007\/s00018-019-03351-7","journal-title":"Cell Mol Life Sci"},{"key":"11300_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.155343","volume":"125","author":"GG Huang","year":"2024","unstructured":"Huang GG, Wang HY, Wang XH, Yang T, Zhang XM, Feng CL et al (2024) Atranorin inhibits Zika virus infection in human glioblastoma cell line SNB-19 via targeting Zika virus envelope protein. Phytomedicine 125:155343. https:\/\/doi.org\/10.1016\/j.phymed.2024.155343","journal-title":"Phytomedicine"},{"key":"11300_CR14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2174\/1871520621666210322094647","volume":"22","author":"AH Tripathi","year":"2022","unstructured":"Tripathi AH, Negi N, Gahtori R, Kumari A, Joshi P, Tewari LM et al (2022) A review of anti-cancer and related properties of lichen-extracts and metabolites. Anticancer Agents Med Chem 22:115\u2013142. https:\/\/doi.org\/10.2174\/1871520621666210322094647","journal-title":"Anticancer Agents Med Chem"},{"key":"11300_CR15","doi-asserted-by":"publisher","first-page":"6828","DOI":"10.1021\/acsomega.3c08136","volume":"9","author":"R Zhou","year":"2024","unstructured":"Zhou R, Liu R, Kang KB, Kim W, Hur JS, Kim H (2024) The depside derivative pericodepside inhibits cancer cell metastasis and proliferation by suppressing epithelial-mesenchymal transition. ACS Omega 9:6828\u20136836. https:\/\/doi.org\/10.1021\/acsomega.3c08136","journal-title":"ACS Omega"},{"key":"11300_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.145896","volume":"320","author":"B Murugesan","year":"2025","unstructured":"Murugesan B, Rathinavel T, Kumar RS, Gomathi M, Maheswari SU, Ameer K et al (2025) Atranorin from lichens act as potential inhibitor for cervical tumor proteins TGFbeta and kinase enzyme CDK4\/CyclinD3: an anti-cancer intervention therapy. Int J Biol Macromol 320:145896. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.145896","journal-title":"Int J Biol Macromol"},{"key":"11300_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ph17101380","volume":"17","author":"M Ensoy","year":"2024","unstructured":"Ensoy M, Cansaran-Duman D (2024) Targeting ferroptosis with small molecule Atranorin (ATR) as a novel therapeutic strategy and providing new insight into the treatment of breast cancer. Pharmaceuticals (Basel) 17:1380. https:\/\/doi.org\/10.3390\/ph17101380","journal-title":"Pharmaceuticals (Basel)"},{"key":"11300_CR18","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.3390\/molecules24071414","volume":"24","author":"YJ Jeon","year":"2019","unstructured":"Jeon YJ, Kim S, Kim JH, Youn UJ, Suh SS (2019) The comprehensive roles of ATRANORIN, a secondary metabolite from the Antarctic lichen Stereocaulon caespitosum, in HCC tumorigenesis. Molecules 24:1414. https:\/\/doi.org\/10.3390\/molecules24071414","journal-title":"Molecules"},{"key":"11300_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.tiv.2010.09.004","volume":"25","author":"M Ba\u010dkorov\u00e1","year":"2011","unstructured":"Ba\u010dkorov\u00e1 M, Ba\u010dkor M, Mike\u0161 J, Jend\u017eelovsk\u00fd R, Fedoro\u010dko P (2011) Variable responses of different human cancer cells to the lichen compounds parietin, atranorin, Usnic acid and gyrophoric acid. Toxicol In Vitro 25:37\u201344. https:\/\/doi.org\/10.1016\/j.tiv.2010.09.004","journal-title":"Toxicol In Vitro"},{"key":"11300_CR20","doi-asserted-by":"publisher","first-page":"26881","DOI":"10.1038\/s41598-025-12725-w","volume":"15","author":"C Damodaran","year":"2025","unstructured":"Damodaran C, Cho JY, G\u00fcng\u00f6r C (2025) Therapeutic resistance and combination therapy for cancer: recent developments and future directions. Sci Rep 15:26881. https:\/\/doi.org\/10.1038\/s41598-025-12725-w","journal-title":"Sci Rep"},{"key":"11300_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71065","volume":"14","author":"W Li","year":"2025","unstructured":"Li W, Xu M, Cheng M, Wei J, Zhu L, Deng Y et al (2025) Current advances and future directions for sensitizing gastric cancer to immune checkpoint inhibitors. Cancer Med 14:e71065. https:\/\/doi.org\/10.1002\/cam4.71065","journal-title":"Cancer Med"},{"key":"11300_CR22","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.tiv.2012.01.017","volume":"26","author":"M Ba\u010dkorov\u00e1","year":"2012","unstructured":"Ba\u010dkorov\u00e1 M, Jend\u017eelovsk\u00fd R, Kello M, Ba\u010dkor M, Mike\u0161 J, Fedoro\u010dko P (2012) Lichen secondary metabolites are responsible for induction of apoptosis in HT-29 and A2780 human cancer cell lines. Toxicol In Vitro 26:462\u2013468. https:\/\/doi.org\/10.1016\/j.tiv.2012.01.017","journal-title":"Toxicol In Vitro"},{"key":"11300_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.112734","volume":"148","author":"LA Roser","year":"2022","unstructured":"Roser LA, Erkoc P, Ingelfinger R, Henke M, Ulsh\u00f6fer T, Schneider AK et al (2022) Lecanoric acid mediates anti-proliferative effects by an M phase arrest in colon cancer cells. Biomed Pharmacother 148:112734. https:\/\/doi.org\/10.1016\/j.biopha.2022.112734","journal-title":"Biomed Pharmacother"},{"key":"11300_CR24","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.7150\/ijms.73701","volume":"19","author":"Z Ni","year":"2022","unstructured":"Ni Z, Nie X, Zhang H, Wang L, Geng Z, Du X et al (2022) Atranorin driven by nano materials SPION lead to ferroptosis of gastric cancer stem cells by weakening the mRNA 5-hydroxymethylcytidine modification of the Xc-\/GPX4 axis and its expression. Int J Med Sci 19:1680\u20131694. https:\/\/doi.org\/10.7150\/ijms.73701","journal-title":"Int J Med Sci"},{"key":"11300_CR25","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1080\/07391102.2020.1734482","volume":"39","author":"A Harikrishnan","year":"2021","unstructured":"Harikrishnan A, Veena V, Lakshmi B, Shanmugavalli R, Theres S, Prashantha CN et al (2021) Atranorin, an antimicrobial metabolite from lichen Parmotrema rampoddense exhibited in vitro anti-breast cancer activity through interaction with Akt activity. J Biomol Struct Dyn 39:1248\u20131258. https:\/\/doi.org\/10.1080\/07391102.2020.1734482","journal-title":"J Biomol Struct Dyn"},{"key":"11300_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.molliq.2024.125743","volume":"413","author":"KN Semenov","year":"2024","unstructured":"Semenov KN, Prokopiev IA, Petukhova NV, Kremenetskaya UA, Senichkina DA, Epifanovskaya OS et al (2024) Atranorin is a novel potential candidate drug for treating myelodysplastic syndrome. J Mol Liq 413:125743. https:\/\/doi.org\/10.1016\/j.molliq.2024.125743","journal-title":"J Mol Liq"},{"key":"11300_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/cbdv.202301229","volume":"20","author":"SB Gaikwad","year":"2023","unstructured":"Gaikwad SB, Mapari SV, Sutar RR, Syed M, Khare R, Behera BC (2023) In\u2005vitro and in\u2005silico studies of lichen compounds Atranorin and salazinic acid as potential antioxidant, antibacterial and anticancer agents. Chem Biodivers 20:e202301229. https:\/\/doi.org\/10.1002\/cbdv.202301229","journal-title":"Chem Biodivers"},{"key":"11300_CR28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cbi.2016.03.012","volume":"250","author":"P Sol\u00e1r","year":"2016","unstructured":"Sol\u00e1r P, Hr\u010dkov\u00e1 G, Kopta\u0161\u00edkov\u00e1 L, Velebn\u00fd S, Sol\u00e1rov\u00e1 Z, Ba\u010dkor M (2016) Murine breast carcinoma 4T1 cells are more sensitive to Atranorin than normal epithelial NMuMG cells in vitro: anticancer and hepatoprotective effects of Atranorin in vivo. Chem Biol Interact 250:27\u201337. https:\/\/doi.org\/10.1016\/j.cbi.2016.03.012","journal-title":"Chem Biol Interact"},{"key":"11300_CR29","doi-asserted-by":"publisher","first-page":"299","DOI":"10.4103\/2221-1691.261810","volume":"9","author":"E Sahin","year":"2019","unstructured":"Sahin E, Psav SD, Avan I, Candan M, Sahinturk V, Koparal AT (2019) Cytotoxic, apoptotic and cell migration inhibitory effects of Atranorin on SPC212 mesothelioma cells. Asia Pac J Trop Biomed 9:299\u2013306","journal-title":"Asia Pac J Trop Biomed"},{"key":"11300_CR30","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.tiv.2017.01.008","volume":"40","author":"A Galanty","year":"2017","unstructured":"Galanty A, Koczurkiewicz P, Wnuk D, Paw M, Karnas E, Podolak I et al (2017) Usnic acid and atranorin exert selective cytostatic and anti-invasive effects on human prostate and melanoma cancer cells. Toxicol In Vitro 40:161\u2013169. https:\/\/doi.org\/10.1016\/j.tiv.2017.01.008","journal-title":"Toxicol In Vitro"},{"key":"11300_CR31","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s10549-020-05627-0","volume":"181","author":"CLT J\u00f8rgensen","year":"2020","unstructured":"J\u00f8rgensen CLT, Forsare C, Bendahl PO, Falck AK, Fern\u00f6 M, L\u00f6vgren K et al (2020) Expression of epithelial-mesenchymal transition-related markers and phenotypes during breast cancer progression. Breast Cancer Res Treat 181:369\u2013381. https:\/\/doi.org\/10.1007\/s10549-020-05627-0","journal-title":"Breast Cancer Res Treat"},{"key":"11300_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/cells8101118","volume":"8","author":"CY Loh","year":"2019","unstructured":"Loh CY, Chai JY, Tang TF, Wong WF, Sethi G, Shanmugam MK et al (2019) The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition: signaling, therapeutic implications, and challenges. Cells 8:1118. https:\/\/doi.org\/10.3390\/cells8101118","journal-title":"Cells"},{"key":"11300_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194985","volume":"13","author":"S Usman","year":"2021","unstructured":"Usman S, Waseem NH, Nguyen TKN, Mohsin S, Jamal A, Teh MT et al (2021) Vimentin is at the heart of epithelial mesenchymal transition (EMT) mediated metastasis. Cancers (Basel) 13:4985. https:\/\/doi.org\/10.3390\/cancers13194985","journal-title":"Cancers (Basel)"},{"key":"11300_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01460-1","volume":"8","author":"ZL Liu","year":"2023","unstructured":"Liu ZL, Chen HH, Zheng LL, Sun LP, Shi L (2023) Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther 8:198. https:\/\/doi.org\/10.1038\/s41392-023-01460-1","journal-title":"Signal Transduct Target Ther"},{"key":"11300_CR35","doi-asserted-by":"publisher","first-page":"13317","DOI":"10.3390\/ijms241713317","volume":"24","author":"SMZ Bokhari","year":"2023","unstructured":"Bokhari SMZ, Hamar P (2023) Vascular endothelial growth factor-D (VEGF-D): an angiogenesis bypass in malignant tumors. Int J Mol Sci 24:13317. https:\/\/doi.org\/10.3390\/ijms241713317","journal-title":"Int J Mol Sci"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11300-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-11300-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11300-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T13:41:05Z","timestamp":1765460465000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-11300-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11300"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-11300-w","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"First author's affiliation has been corrected","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"153"}}